Drugs / SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03
SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04762680 | Feb 2021 → Jun 2023 | COVID-19 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04762680 ↗ |
| Modality | Vaccine | “SARS-CoV-2 Recombinant Protein Vaccines” NCT04762680 ↗ |
| Route | Intramuscular | “Route of administration: Intramuscular injection” NCT04762680 ↗ |